Entrada Therapeutics’ next-generation Duchenne muscular dystrophy drug disappointed in an early readout, sending the stock sharply lower and raising questions about the company’s competitiveness in exon-skipping. The program is part of a crowded wave of mutation-directed therapies designed to improve dystrophin production compared with the first approvals. Investors had expected the early trial data to validate Entrada’s platform approach and differentiation. The market reaction highlights the high bar for new entrants in DMD, where incremental improvements in protein production, delivery, and clinical endpoints can drive meaningful valuation shifts. More broadly, the setback may tighten scrutiny on next-generation exon-skipping candidates as companies race to show durable, clinically meaningful benefit beyond early biomarker signals.